Ignite Creation Date:
2024-05-06 @ 12:52 AM
Last Modification Date:
2024-10-26 @ 10:56 AM
Study NCT ID:
NCT01678807
Status:
COMPLETED
Last Update Posted:
2017-09-15
First Post:
2012-08-31
Brief Title:
Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents MK-8237-008
Sponsor:
ALK-Abelló AS
Organization:
ALK-Abelló AS
Study Overview
Official Title:
Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents Protocol 008
Status:
COMPLETED
Status Verified Date:
2017-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety of two doses 6 Development Units DU and 12 DU of MK-8237 sublingual tablets compared to Placebo in adolescents with house dust mite-induced allergic rhinitisrhinoconjunctivitis The primary hypothesis is that at least one dose of MK-8237 sublingual tablet is safe and well-tolerated in adolescents with house dust mite-induced allergic rhinitisrhinoconjunctivitis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MK-8237-008 | OTHER | Merck Protocol Number | None |